Yifenidone
Small moleculeexperimental
Clinical trial activity
7 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started May 15, 2017 (NCT03092102)
Timeline
Indications
Mechanism of action
- Transforming growth factor beta-2INHIBITOR
TGFB2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- hec585
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07082842 | Phase 3 | Oct 9, 2025 | Sunshine Lake Pharma Co., Ltd. |
| NCT05468346 | Phase 1 | Aug 31, 2022 | Sunshine Lake Pharma Co., Ltd. |
| NCT05139719 | Phase 2 | Dec 31, 2021 | Sunshine Lake Pharma Co., Ltd. |
| NCT05060822 | Phase 2 | Jun 30, 2021 | Sunshine Lake Pharma Co., Ltd. |
| NCT05383131 | Phase 1 | Jun 23, 2021 | Sunshine Lake Pharma Co., Ltd. |
| NCT04512170 | Phase 1 | Jul 13, 2020 | Sunshine Lake Pharma Co., Ltd. |
| NCT03092102 | Phase 1 | May 15, 2017 | Sunshine Lake Pharma Co., Ltd. |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sunshine Lake Pharma Co., Ltd. | For profit | 7 | 7 | 3 | 2017 |
1 organizations
Page 1 / 1